Posted by SLS on August 31, 2010, at 11:18:00
In reply to Reboxetine/Edronax, posted by atypical on August 29, 2010, at 23:36:22
> In Stahl's Cambridge Online Prescriber's Guide I noticed this drug is listed for depression and dysthymia. And it acts on norepinephrine (not serotonin -- I take MAOI so wouldn't be able to take serotinergic drug). But, alas, it is not available in the US. Is it in process? Or is it just going to be a UK drug.
I haven't seen anything that would lead me to believe that reboxetine is being developed in the US for marketing. It doesn't seem to be as effective as desipramine, a TCA that is selective for NE reuptake inhibition. There are other pharmacological differences between the two drugs as well. It is difficult to pinpoint which properties are most important for its mechanisms of action as an antidepressant.
- Scott
The measure of achievement lies not in how high the mountain,
but in how hard the climb.The measure of success lies only in how high one feels he must
climb to get there.
poster:SLS
thread:960569
URL: http://www.dr-bob.org/babble/20100829/msgs/960801.html